Silo Pharma Expanding Drug Delivery IP Portfolio
Robin Lefferts
September 7th, 2021
App, Exclusive, Psychedelics, Top Story
While inflammation in general contributes to a wide range of diseases, swelling of the central nervous system (CNS) is associated with conditions including Parkinson’s disease, multiple sclerosis, chronic back pain, bipolar disorder, cancer cachexia, Alzheimer’s disease, and many more. Treatment of inflammation in the CNS is difficult due to the role of the blood-brain barrier in protecting the brain and spinal cord from harmful agents, a system that often blocks medicines like anti-inflammatory drugs from being delivered to those tissues.
Silo Pharma Inc. (OTCQB: SILO) has been developing a delivery system based on homing peptides that may greatly enhance the delivery of active ingredients like non-steroidal anti-inflammatory drugs (NSAIDs) and even psychedelic agents like psilocybin to the CNS. Silo was recently given a Notice of Allowance of a U.S. patent for its CNS Homing Peptide and is awaiting approval of more international patents to further protect its research and discoveries.
Carving Out a Niche
Silo Pharma’s approach is to merge traditional therapeutics with psychedelic compounds with the goal of enhancing treatment of neurological disorders. Psychedelics like psilocybin, ketamine, and LSD have shown tremendous promise in treating psychiatric disorders like anxiety, depression, and addiction. These applications of psychedelics have been widely publicized and have contributed greatly to the destigmatization of the idea of psychedelics as medicine.
Click here to receive investor information and corporate updates
The anti-inflammatory effects of psychedelics are a bit less well known, but very promising in their own right. This is where Silo Pharma is focused, and the company has been very active in licensing its technology to, and partnering with, research organizations in order to expedite and enhance its reach.
Recent examples of these agreements are plentiful. Silo has a sponsored research agreement with the University of California San Francisco in clinical trials to determine the effects of psilocybin on inflammation levels of Parkinson’s disease, bipolar disorder, and chronic back pain patients. Silo has sublicensed its delivery technology to researchers studying the treatment of neuroinflammatory pain in cancer patients. The company has licensed its delivery system, the one that was recently given a Notice of Allowance, from the University of Maryland Baltimore for use in studies of the treatment of multiple sclerosis and other neuroinflammatory conditions. Additionally, Silo has extended an option agreement with the University of Maryland for research into potential treatments for rheumatoid arthritis.
Silo is also advancing transdermal delivery technologies in a joint venture with Zylo Therapeutics. Zylo’s patented Z-pod™ delivery system uses silica particles to enhance the delivery of transdermal active ingredients, and the joint venture is investigating such delivery of ketamine. When discussing Z-pod technology, President of the Nano Dermatology Society Adnan Nasir, M.D. said, “The fourth-generation of drug delivery has arrived. Combining tiny particles that do not require needles or ablation with sustained release over a 24-hour period, without a patch, is simply transformative. The clinical applications are endless.”
Patented Delivery Platform
All of these studies and partnerships, while unique in their own ways, together serve a larger purpose for Silo Pharma. As each of the research projects advances, the effectiveness of the company’s patented drug delivery system can be further validated. The method of delivery lies at the heart of Silo’s business and is the centerpiece of the company’s patent filings. With the US patent secure and three more pending, Silo has applied with the Patent Cooperation Treaty organization to extend intellectual property protection to the over 150 countries signed on to the treaty.
Pharmaceutical development companies advance particular drug candidates through clinical trials with the hope of proving efficacy and gaining approval. If successful, they either commercialize the drug themselves or partner with (or sell to) companies that can commercialize them. A failed clinical trial can be the death knell for these organizations, depending on their size and resources.
Silo’s approach mitigates this type of risk. The company’s fortunes are not tied to the success or failure of any one clinical trial or drug candidate. Rather, the accumulation of studies and partnerships and licensing agreements have an additive effect on both revenues and validation of the technology. And the potential for the platform is much larger than any one condition or potential treatment. The granted US patent covers the Central Nervous System Homing Peptide technology, while the pending patents (both US and international) more specifically cover the delivery of psilocybin and NSAIDs, both alone and in combination, to the CNS.
As Eric Weisblum, Silo’s Chairman and CEO, stated, “The ability to deliver traditional therapeutics, psilocybin or other psychedelic drugs directly to targeted areas of the body with this technology could be revolutionary by increasing the efficacy of the treatment while reducing toxicity and the amount of medication needed.”
Click here to receive investor information and corporate updates
Keep an eye on Silo Pharma as it continues to expand its reach through more licensing agreements and research partnerships. These arrangements are not capital-intensive and position Silo to reap long-term royalty income from a number of sources. Additionally, the company has applied to uplist to the NASDAQ exchange, a move which could open up access to a much broader investment community. Stay tuned.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Robin Lefferts
Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Matthew (Matt) Karnes has over 20 years of diverse finance and accounting experience. Prior to founding GreenWave Advisors LLC, Matt worked in equity research focusing on the Radio Broadcasting and Cable Television industries for First Union Securities.
Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
